Mektovi (binimetinib) — CareFirst (Caremark)

Initial criteria

• Used as a single agent for treatment of Langerhans cell histiocytosis

Reauthorization criteria

• Continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen

Approval duration

12 months